EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Longer vs. shorter all-oral bedaquiline-based regimens for drug-resistant tuberculosis: real-world evidence from a high-burden setting

Rashmi Ratnam, Parul Jain, Ram Awadh Singh Kushwaha, Amita Jain, Urmila Singh, Surya Kant

Infection · 2026-10 · 54 (5) · 2579-2587

DOI: 10.1007/s15010-026-02884-x ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Infection, online erschienen am 15.07.2026. Verfasst von Rashmi Ratnam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, 226003, India. Hauptthemen laut MEDLINE: Antitubercular Agents, Diarylquinolines, Tuberculosis, Multidrug-Resistant. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The World Health Organization recommends all-oral bedaquiline-based regimens for drug-resistant tuberculosis (DR-TB), including a longer M/XDR-TB regimen (18-20 months) and a shorter RR/MDR-TB regimen (9-11 months). Comparative effectiveness data under routine programmatic conditions remain limited. OBJECTIVE: To compare clinical and microbiological outcomes of longer versus shorter all-oral treatment regimens. METHODS: We conducted a prospective observational cohort study between January and December 2022. Patients with pulmonary or extrapulmonary RR/MDR-TB were enrolled and treated according to national programmatic guidelines. Six-month culture conversion and end-of-treatment clinical outcomes were compared between longer and shorter all-oral bedaquiline-based regimens using multivariable logistic regression adjusted for pre-specified confounders. RESULTS: Of 1427 patients screened, 894 (62.6%) were included; 691 (77.3%) received the longer regimen and 203 (22.7%) the shorter regimen. Baseline demographic and clinical characteristics were broadly comparable, although resistance profiles differed because regimen allocation was guided by drug susceptibility testing and programmatic eligibility criteria. Six-month culture results were available for 778 (87.0%) patients; 96 (10.7%) died and 20 (2.3%) were lost to follow-up. Culture conversion was significantly higher with the longer regimen than the shorter regimen (579/596, 97.1% vs. 146/182, 80.2%; p < 0.001). In intention-to-treat analysis, favorable outcomes occurred in 525/691 (76.0%) patients receiving the longer regimen and 135/203 (66.5%) receiving the shorter regimen (p = 0.006). The longer regimen was independently associated with favorable outcomes (adjusted odds ratio 1.58, 95% CI 1.15-2.17; p = 0.004). CONCLUSIONS: Baseline demographic and clinical characteristics were broadly comparable, although resistance profiles differed because regimen allocation was guided by drug susceptibility testing and programmatic eligibility criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsDiarylquinolinesTuberculosis, Multidrug-ResistantAdultFemaleHumansMaleMiddle AgedAdministration, OralMycobacterium tuberculosisProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

BedaquilineCulture ConversionDrug Resistance TuberculosisTreatment Outcomes

Substanzen

Antitubercular AgentsbedaquilineDiarylquinolines

Autor:innen und Institutionen

  • Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, 226003, India.
  • Department of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, 226003, India. parulkgmu@gmail.com.
  • Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, 226003, India. kushwaharas2024@gmail.com.
  • Department of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, 226003, India.

Zitieren

APA

Ratnam, R., Jain, P., Kushwaha, R. A. S., Jain, A., Singh, U., & Kant, S. (2026). Longer vs. shorter all-oral bedaquiline-based regimens for drug-resistant tuberculosis: real-world evidence from a high-burden setting. Infection, 54(5), 2579-2587. https://doi.org/10.1007/s15010-026-02884-x

Vancouver

Ratnam R, Jain P, Kushwaha RAS, Jain A, Singh U, Kant S. Longer vs. shorter all-oral bedaquiline-based regimens for drug-resistant tuberculosis: real-world evidence from a high-burden setting. Infection. 2026;54(5):2579-2587. doi:10.1007/s15010-026-02884-x

BibTeX
@article{Ratnam2026,
  author = {Ratnam, Rashmi and Jain, Parul and Kushwaha, Ram Awadh Singh and Jain, Amita and Singh, Urmila and Kant, Surya},
  title = {Longer vs. shorter all-oral bedaquiline-based regimens for drug-resistant tuberculosis: real-world evidence from a high-burden setting},
  journal = {Infection},
  year = {2026},
  volume = {54},
  number = {5},
  pages = {2579--2587},
  doi = {10.1007/s15010-026-02884-x}
}
Kostenlos starten →